| Heading: |
Cancer: Drugs |
| Question ID: |
1805855 |
| UIN: |
54483 |
| House: |
Commons |
| Date tabled: |
2025-05-22 |
| Asking Member ID: |
5207 |
| Asking Member display name: |
Clive Jones
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Clive Jones
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of the introduction of the National Institute for Health and Care Excellence’s severity modifier on the availability of cancer medici |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-02 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence (NICE) carried out a review of the severity modifier in 2024 and found that it is operating as intended. Since its introduction, the severity modifier has resulted in a higher approval rate for cancer ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |